Skip to main content

Table 1 Baseline clinical and hemodynamic data (n = 54)

From: Quality of life as a prognostic marker in pulmonary arterial hypertension

Age (years) 44 ± 12
Sex (f/m) 45/9
Etiology n (%)  
Idiopathic 37 (68)
Associated to  
Schistosomiasis 7 (13)
CTD 8 (15)
CHD 2 (4)
NYHA functional class n (%)  
II 14 (26)
III 28 (52)
IV 12 (22)
6MWT (m) 418 ± 121
mPAP (mmHg) 64 ± 17
PAOP (mmHg) 10 ± 2
Cardiac output (L/min) 4 ± 1
PVR (WU) 15 ± 8
Therapy n (%)  
ERA 46 (85)
PDE-5 inhibitors 8 (15)
  1. CTD Connective tissue disease, CHD Congenital heart disease, NYHA New York Heart Association, 6MWT Length in non-encouraged six-minute-walk test, RAP Right Atrial Pressure, mPAP Mean Pulmonary Artery Pressure, PAOP Pulmonary Artery Occlusion Pressure, PVR Pulmonary Vascular Resistance, ERA Endothelin Receptor Antagonists, PDE-5 Phosphodiesterase-5 inhibitor.